<DOC>
	<DOCNO>NCT02528357</DOCNO>
	<brief_summary>This first time human ( FTIH ) , open-label , non-randomized , multicenter study design evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics , preliminary clinical activity GSK3174998 administer intravenously subject select advanced recurrent solid tumor . This dose-escalation study ass safety , activity GSK3174998 monotherapy ( Part 1 ) , combination pembrolizumab ( Part 2 ) , potentially combination additional therapy . The study conduct 2 part , part consist dose-escalation phase follow cohort expansion phase . Part 1 evaluate GSK3174998 monotherapy , Part 2 evaluate GSK3174998 combination pembrolizumab . GSK3174998 first evaluate monotherapy escalating dos . Once dose GSK3174998 identify tolerable demonstrates pharmacodynamic activity , enrollment Part 2 may begin . In Part 2 , escalate dos GSK3174998 evaluate fixed dos pembrolizumab . The study enroll approximately 264 subject different tumor type ( approximately 144 subject Parts 1A 2A [ dose escalation ] ; approximately 120 subject Parts 1B 2B [ cohort expansion ] ) . The maximum duration treatment GSK3174998 plus minus pembrolizumab 2 year 35 cycle , whichever come first . The follow-up period safety assessment minimum 3 month date last dose . The post-treatment follow-up period include disease assessment every 12 week .</brief_summary>
	<brief_title>GSK3174998 Alone With Pembrolizumab Subjects With Advanced Solid Tumors ( ENGAGE-1 )</brief_title>
	<detailed_description />
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>Provide sign , write informed consent . Male female subject , age &gt; =18 year ( time consent obtain ) . Histological documentation locally advance , recurrent metastatic solid malignancy progress standard therapy appropriate specific tumor type , standard therapy proven ineffective , intolerable , consider inappropriate . Subjects receive 5 prior line therapy advance disease include standard care investigational therapy . Subjects whose cancer harbor molecular alteration target therapy standard care receive health authority approve appropriate target therapy tumor type enrollment . Subjects follow solid tumor eligible screening : Nonsmall cell lung cancer ( NSCLC ) , Squamous cell carcinoma head neck ( SCCHN ) , Renal cell carcinoma ( RCC ) , melanoma , bladder , Triplenegative breast cancer ( TNBC ) , Colorectal carcinoma display microsatellite instability ( MSI CRC ) . A biopsy tumor tissue obtain anytime initial diagnosis study entry . Although fresh biopsy obtain screening preferred , archival tumor specimen acceptable feasible obtain fresh biopsy . For Part 1B Part 2B , archival tumor specimen must obtain within 3 month start study drug . Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 . Palpable lesion measurable radiologic photographic evaluation may utilize measurable lesion . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 . Life expectancy least 12 week . Adequate organ function define System Laboratory Values ; Hematologic ( Absolute neutrophil count [ ANC ] &gt; =1.5x10^9/ liter [ L ] , Lymphocyte count &gt; 1,000/cubic millimeter [ mm^3 ] , Hemoglobin &gt; =9 grams/deciliter [ g/dL ] , Platelets &gt; =100x10^9/L ) , Hepatic ( Total bilirubin &lt; =1.5x upper limit normal [ ULN ] [ For subject Gilbert 's Syndrome , direct bilirubin &lt; =35 % , &lt; =3.0xULN ] , alanine aminotransferase [ ALT ] &lt; =1.5xULN ) ; Renal ( Serum Creatinine &lt; =1.5xULN OR Calculated creatinine clearance [ CrCl &gt; 50 mL/min ) Endocrine ( Thyroid stimulate hormone [ TSH ] within normal limit . If TSH within normal limit baseline , subject may still eligible total T3 free T3 free T4 within normal limit . QT duration correct heart rate Fridericia 's formula ( QTcF ) &lt; 450 msec &lt; 480 millisecond ( msec ) subject bundle branch block . Female subject male subject female partner child bear potential must comply adequate contraception requirement time first dose study medication 120 day last dose study medication . Prior treatment follow agent ( last dose prior treatment first dose GSK3174998 ) : Tumor necrosis factor receptor ( TNFR ) agonist , include OX40 , CD27 , CD137 ( 41BB ) , CD357 ( GITR ) : time ; Checkpoint inhibitor , include PD1 , PDL1 , anticytotoxic Tlymphocyte antigen 4 ( CTLA4 ) inhibitor : within 4 week . Prior allogeneic autologous bone marrow transplantation solid organ transplantation . Active residual toxicity prior therapy . Secondary malignancy . Brain metastasis . Active autoimmune disease require systemic treatment within last 2 year . Active infection , know human immunodeficiency virus infection , positive test hepatitis B surface antigen hepatitis C. Current active liver biliary disease . Acute diverticulitis , inflammatory bowel disease , intraabdominal abscess , gastrointestinal obstruction within past 6 month . Severe hypersensitivity monoclonal antibody ( mAbs ) . Recent ( within 6 month ) history second degree ( Type II ) third degree atrioventricular ( AV ) block cardiomyopathy , myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting , bypass grafting ; Class II , III , IV heart failure , symptomatic pericarditis . Current history idiopathic pulmonary fibrosis , interstitial lung disease , organize pneumonia . History ( noninfectious ) pneumonitis require steroid current pneumonitis . Uncontrolled symptomatic ascites pleural effusion within 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>mAb</keyword>
	<keyword>GSK3174998</keyword>
	<keyword>anticancer agent</keyword>
	<keyword>checkpoint</keyword>
	<keyword>OX40</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>MK-3475-167</keyword>
	<keyword>solid tumor</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>KEYNOTE-167</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>antitumor</keyword>
</DOC>